
RealRate

PHARMACEUTICAL 2021

FIBROGEN INC Rank 144 of 409





RealRate

PHARMACEUTICAL 2021

FIBROGEN INC Rank 144 of 409



The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 95% points. The greatest weakness of FIBROGEN INC is the variable Research and Development, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is -48%, being 307% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	755,110
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	163,187
Liabilities, Non-Current	178,116
Other Assets	38,083
Other Compr. Net Income	-3,752
Other Expenses	9,229
Other Liabilities	44,088
Other Net Income	2,949
Property and Equipment	33,647
Research and Development	252,924
Revenues	176,319
Selling, General and Administrative Expense	106,406

Output Variable	Value in 1000 USD
Assets	826,840
Liabilities	385,391
Expenses	368,559
Stockholders Equity	441,449
Net Income	-189,291
Comprehensive Net Income	-191,167
Economic Capital Ratio	-48%

